News & Events Year None2019201820172016201520142013201220112009 05/24/19 REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform 05/15/19 REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies 05/08/19 REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference 05/07/19 REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 04/30/19 REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights 04/17/19 REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer 04/15/19 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
